keyword
MENU ▼
Read by QxMD icon Read
search

Zaire

keyword
https://www.readbyqxmd.com/read/28216187/recombinant-proteins-of-zaire-ebolavirus-induce-potent-humoral-and-cellular-immune-responses-and-protect-against-live-virus-infection-in-mice
#1
Axel T Lehrer, Teri-Ann S Wong, Michael M Lieberman, Tom Humphreys, David E Clements, Russell R Bakken, Mary Kate Hart, William D Pratt, John M Dye
Infections with filoviruses in humans are highly virulent, causing hemorrhagic fevers which result in up to 90% mortality. In addition to natural infections, the ability to use these viruses as bioterrorist weapons is of significant concern. Currently, there are no licensed vaccines or therapeutics available to combat these infections. The pathogenesis of disease involves the dysregulation of the host's immune system, which results in impairment of the innate and adaptive immune responses, with subsequent development of lymphopenia, thrombocytopenia, hemorrhage, and death...
February 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28216184/vaccine-development-for-emerging-virulent-infectious-diseases
#2
Joel N Maslow
The recent outbreak of Zaire Ebola virus in West Africa altered the classical paradigm of vaccine development and that for emerging infectious diseases (EIDs) in general. In this paper, the precepts of vaccine discovery and advancement through pre-clinical and clinical assessment are discussed in the context of the recent Ebola virus, Middle East Respiratory Syndrome coronavirus (MERS-CoV), and Zika virus outbreaks. Clinical trial design for diseases with high mortality rates and/or high morbidity in the face of a global perception of immediate need and the factors that drive design in the face of a changing epidemiology are presented...
February 16, 2017: Vaccine
https://www.readbyqxmd.com/read/28167539/chemically-modified-human-serum-albumin-potently-blocks-entry-of-ebola-pseudoviruses-and-virus-like-particles
#3
Haoyang Li, Fei Yu, Shuai Xia, Yufeng Yu, Qian Wang, Ming Lv, Yan Wang, Shibo Jiang, Lu Lu
Ebola virus (EBOV), causative pathogen of the deadly Ebola virus disease (EVD), can be transmitted via contact with EVD patients, including sexual contact with EVD survivors. At present, no licensed vaccine or therapeutic is available. In this study, we compared eight anhydride-modified proteins for their inhibitory activity against entry of the pseudovirus (PsV) carrying the envelope glycoprotein (GP) of EBOV Zaire or Sudan species. We found that 3-hydroxyphthalic anhydride-modified human serum albumin (HP-HSA) was most effective in inhibiting entry of both Zaire-PsV and Sudan-PsV, with EC50 at nanomolar level, more potent than EBOV-neutralizing antibody, MIL77-2 (4G7)...
February 6, 2017: Antimicrobial Agents and Chemotherapy
https://www.readbyqxmd.com/read/28153004/efficacy-of-artemether-lumefantrine-artesunate-amodiaquine-and-dihydroartemisinin-piperaquine-for-treatment-of-uncomplicated-plasmodium-falciparum-malaria-in-angola-2015
#4
Mateusz M Plucinski, Pedro Rafael Dimbu, Aleixo Panzo Macaia, Carolina Miguel Ferreira, Claudete Samutondo, Joltim Quivinja, Marília Afonso, Richard Kiniffo, Eliane Mbounga, Julia S Kelley, Dhruviben S Patel, Yun He, Eldin Talundzic, Denise O Garrett, Eric S Halsey, Venkatachalam Udhayakumar, Pascal Ringwald, Filomeno Fortes
BACKGROUND: Recent anti-malarial resistance monitoring in Angola has shown efficacy of artemether-lumefantrine (AL) in certain sites approaching the key 90% lower limit of efficacy recommended for artemisinin-based combination therapy. In addition, a controversial case of malaria unresponsive to artemisinins was reported in a patient infected in Lunda Sul Province in 2013. METHODS: During January-June 2015, investigators monitored the clinical and parasitological response of children with uncomplicated Plasmodium falciparum infection treated with AL, artesunate-amodiaquine (ASAQ), or dihydroartemisinin-piperaquine (DP)...
February 2, 2017: Malaria Journal
https://www.readbyqxmd.com/read/28135118/ebola-virus-and-marburg-virus-in-human-milk-are-inactivated-by-holder-pasteurization
#5
Erin Hamilton Spence, Monica Huff, Karen Shattuck, Amy Vickers, Nadezda Yun, Slobodan Paessler
BACKGROUND: Potential donors of human milk are screened for Ebola virus (EBOV) using standard questions, but testing for EBOV and Marburg virus (MARV) is not part of routine serological testing performed by milk banks. Research aim: This study tested the hypothesis that EBOV would be inactivated in donor human milk (DHM) by standard pasteurization techniques (Holder) used in all North American nonprofit milk banks. METHODS: Milk samples were obtained from a nonprofit milk bank...
January 1, 2017: Journal of Human Lactation: Official Journal of International Lactation Consultant Association
https://www.readbyqxmd.com/read/28096532/a-sensitive-and-specific-point-of-care-detection-assay-for-zaire-ebola-virus
#6
Xiao-Ai Zhang, Sabrina Li, Jesus Ching, Hui-Ying Feng, Kun Yang, David L Dolinger, Long-Di Zhang, Pan-He Zhang, Wei Liu, Wu-Chun Cao
No abstract text is available yet for this article.
January 18, 2017: Emerging Microbes & Infections
https://www.readbyqxmd.com/read/28059773/attosecond-physics-at-the-nanoscale
#7
Marcelo F Ciappina, J Perez-Hernandez, Alexandra Landsman, William Okell, Sergey Zherebtsov, Benjamin Förg, Johannes Schötz, Lennart Seiffert, Thomas Fennel, Tahir Shaaran, Tomas Zimmermann, Alexis Chacón, Roland Guichard, Amelle Zair, John Tisch, J Marangos, Tobias Witting, Avi Braun, Stefan Maier, Luis Roso, Michael Krüger, Peter Hommelhoff, Matthias Kling, Ferenc Krausz, Maciej Lewenstein
Recently two emerging areas of research, attosecond and nanoscale physics, have started to come together. Attosecond physics deals with phenomena occurring when ultrashort laser pulses, with duration on the femto- and sub-femtosecond time scales, interact with atoms, molecules or solids. The laser-induced electron dynamics occurs natively on a timescale down to a few hundred or even tens of attoseconds, which is comparable with the optical field. For comparison, the revolution of an electron on a 1s orbital of a hydrogen atom is 152 as...
January 6, 2017: Reports on Progress in Physics
https://www.readbyqxmd.com/read/28017403/efficacy-and-effectiveness-of-an-rvsv-vectored-vaccine-in-preventing-ebola-virus-disease-final-results-from-the-guinea-ring-vaccination-open-label-cluster-randomised-trial-ebola-%C3%A3-a-suffit
#8
Ana Maria Henao-Restrepo, Anton Camacho, Ira M Longini, Conall H Watson, W John Edmunds, Matthias Egger, Miles W Carroll, Natalie E Dean, Ibrahima Diatta, Moussa Doumbia, Bertrand Draguez, Sophie Duraffour, Godwin Enwere, Rebecca Grais, Stephan Gunther, Pierre-Stéphane Gsell, Stefanie Hossmann, Sara Viksmoen Watle, Mandy Kader Kondé, Sakoba Kéïta, Souleymane Kone, Eewa Kuisma, Myron M Levine, Sema Mandal, Thomas Mauget, Gunnstein Norheim, Ximena Riveros, Aboubacar Soumah, Sven Trelle, Andrea S Vicari, John-Arne Røttingen, Marie-Paule Kieny
BACKGROUND: rVSV-ZEBOV is a recombinant, replication competent vesicular stomatitis virus-based candidate vaccine expressing a surface glycoprotein of Zaire Ebolavirus. We tested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts of recently confirmed cases in Guinea, west Africa. METHODS: We did an open-label, cluster-randomised ring vaccination trial (Ebola ça Suffit!) in the communities of Conakry and eight surrounding prefectures in the Basse-Guinée region of Guinea, and in Tomkolili and Bombali in Sierra Leone...
February 4, 2017: Lancet
https://www.readbyqxmd.com/read/28017399/safety-and-immunogenicity-of-a-recombinant-adenovirus-type-5-vector-based-ebola-vaccine-in-healthy-adults-in-sierra-leone-a-single-centre-randomised-double-blind-placebo-controlled-phase-2-trial
#9
Feng-Cai Zhu, Alie H Wurie, Li-Hua Hou, Qi Liang, Yu-Hua Li, James B W Russell, Shi-Po Wu, Jing-Xin Li, Yue-Mei Hu, Qiang Guo, Wen-Bo Xu, Abdul R Wurie, Wen-Juan Wang, Zhe Zhang, Wen-Jiao Yin, Manal Ghazzawi, Xu Zhang, Lei Duan, Jun-Zhi Wang, Wei Chen
BACKGROUND: A recombinant adenovirus type-5 vector-based vaccine expressing the glycoprotein of Ebola Zaire Makona variant showed good safety and immunogenicity in a phase 1 trial of healthy Chinese adults. We aimed to assess the safety and immunogenicity of this vaccine in healthy adults in Sierra Leone and to determine the optimal dose. METHODS: We did a single-centre, randomised, double-blind, placebo-controlled, phase 2 clinical trial at Sierra Leone-China Friendship Hospital, Freetown, Sierra Leone...
December 22, 2016: Lancet
https://www.readbyqxmd.com/read/28003349/assessment-and-optimization-of-the-genexpert-diagnostic-platform-for-detection-of-ebola-virus-rna-in-seminal-fluid
#10
James Pettitt, Elizabeth Higgs, Mosoka Fallah, Martha Nason, Eric Stavale, Jonathan Marchand, Cavan Reilly, Kenneth Jensen, Bonnie Dighero-Kemp, Kaylie Tuznik, James Logue, Fatorma Bolay, Lisa Hensley
Recent studies have suggested that Ebola virus (EBOV) RNA potentially present in the semen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribute to sexual transmission of EVD and generate new clusters of cases in regions previously declared EBOV free. These findings drive the immediate need for a reliable, rapid, user-friendly assay for detection of EBOV RNA in semen that is deployable to multiple sites across Western Africa. In this study, we optimized the Xpert EBOV assay for semen samples by adding dithiothreitol...
December 21, 2016: Journal of Infectious Diseases
https://www.readbyqxmd.com/read/27998698/ocular-complications-in-survivors-of-the-ebola-outbreak-in-guinea
#11
Esther Hereth He'bert, Mamadou Oury Bah, Jean François E'tard, Mamadou Saliou Sow, Serge Resnikoff, Christine Fardeau, Abdoulaye Toure', Alexis Niouma Ouendeno, Isaac Ceougna Sagno, Laura March, Suzanne Izard, Pierre Louis Lama, Moumié Barry, Eric Delaporte
PURPOSE: The Ebola outbreak of 2013-2016 severely affected West Africa and resulted in 2544 deaths and 1270 survivors in Guinea, the country where it began. This Ebola virus was the Zaire strain of the virus family Filoviridae. In this outbreak the case fatality rate was about 67%. The survivors, declared cured after two negative blood PCR results, face psychosocial disorders, rheumatic, ear-nose-throat, neurocognitive, and ophthalmological complications. The goal of this study was to detect and describe ocular complications afflicting these survivors and to observe their occurrence and recurrences...
December 17, 2016: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/27974555/vp24-karyopherin-alpha-binding-affinities-differ-between-ebolavirus-species-influencing-interferon-inhibition-and-vp24-stability
#12
Toni M Schwarz, Megan R Edwards, Audrey Diederichs, Joshua B Alinger, Daisy W Leung, Gaya K Amarasinghe, Christopher F Basler
: Zaire ebolavirus (EBOV), Bundibugyo ebolavirus (BDBV), and Reston ebolavirus (RESTV) belong to the same genus but exhibit different virulence properties. VP24 protein, a structural protein present in all family members, blocks interferon (IFN) signaling and likely contributes to virulence. Inhibition of IFN signaling by EBOV VP24 (eVP24) involves its interaction with the NPI-1 subfamily of karyopherin alpha (KPNA) nuclear transporters. Here, we evaluated eVP24, BDBV VP24 (bVP24), and RESTV VP24 (rVP24) interactions with three NPI-1 subfamily KPNAs (KPNA1, KPNA5, and KPNA6)...
February 15, 2017: Journal of Virology
https://www.readbyqxmd.com/read/27942840/expression-of-an-immunogenic-ltb-based-chimeric-protein-targeting-zaire-ebolavirus-epitopes-from-gp1-in-plant-cells
#13
Regina Ríos-Huerta, Elizabeth Monreal-Escalante, Dania O Govea-Alonso, Carlos Angulo, Sergio Rosales-Mendoza
An antigenic protein targeting two epitopes from the Zaire ebolavirus GP1 protein was expressed in plant cells rendering an antigen capable of inducing humoral responses in mouse when administered subcutaneously or orally. The 2014 Ebola outbreak made clear that new treatments and prophylactic strategies to fight this disease are needed. Since vaccination is an intervention that could achieve the control of this epidemic disease, exploring the production of new low-cost vaccines is a key path to consider; especially in developing countries...
December 9, 2016: Plant Cell Reports
https://www.readbyqxmd.com/read/27925844/a-two-dose-heterologous-prime-boost-vaccine-regimen-eliciting-sustained-immune-responses-to-ebola-zaire-could-support-a-preventive-strategy-for-future-outbreaks
#14
Georgi Shukarev, Benoit Callendret, Kerstin Luhn, Macaya Douoguih
The consequences of the 2013-16 Ebola Zaire virus disease epidemic in West Africa were grave. The economies, healthcare systems and communities of Guinea, Sierra Leone and Liberia were devastated by over 18 months of active Ebola virus transmission, followed by sporadic resurgences potentially related to sexual transmission by survivors with viral persistence in body fluids following recovery. The need to develop and implement strategies to prevent and mitigate future outbreaks is now beyond dispute. The potential for unpredictable outbreaks of indeterminate duration, and control challenges posed by the possibility of sporadic re-emergence, mean that implementation of an effective vaccination program for outbreak containment necessitates a vaccine providing durable immunity...
February 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/27910909/the-disinfection-characteristics-of-ebola-virus-outbreak-variants
#15
Bradley W M Cook, Todd A Cutts, Aidan M Nikiforuk, Anders Leung, Darwyn Kobasa, Steven S Theriault
The recent Ebola virus outbreak in West Africa has forced experts to re-evaluate their understanding of how to best disinfect areas contaminated with infectious bodily fluids. Recent research has found that Ebola virus remains viable in blood for 7-10 days making appropriate disinfection crucial to infection control. We sought to determine if the three most important outbreak variants of Zaire ebolavirus (Mayinga, Kikwit and Makona) exhibit separate phenotypes when challenged with a range of sodium hypochlorite (NaOCl) concentrations or 70% ethanol (EtOH) at average West African temperature...
December 2, 2016: Scientific Reports
https://www.readbyqxmd.com/read/27902321/the-serology-of-ebolavirus-a-wider-geographical-range-a-wider-genus-of-viruses-or-a-wider-range-of-virulence
#16
Magdalena Formella, Derek Gatherer
Viruses of the genus Ebolavirus are the causative agents of Ebola virus disease (EVD), of which there have been only 25 recorded outbreaks since the discovery of Zaire and Sudan ebolaviruses in the late 1970s. Until the west African outbreak commencing in late 2013, EVD was confined to an area of central Africa stretching from the coast of Gabon through the Congo river basin and eastward to the Great Lakes. Nevertheless, population serological studies since 1976, most of which were carried out in the first two decades after that date, have suggested a wider distribution and more frequent occurrence across tropical Africa...
December 2016: Journal of General Virology
https://www.readbyqxmd.com/read/27887599/how-severe-and-prevalent-are-ebola-and-marburg-viruses-a-systematic-review-and-meta-analysis-of-the-case-fatality-rates-and-seroprevalence
#17
Luke Nyakarahuka, Clovice Kankya, Randi Krontveit, Benjamin Mayer, Frank N Mwiine, Julius Lutwama, Eystein Skjerve
BACKGROUND: Ebola and Marburg virus diseases are said to occur at a low prevalence, but are very severe diseases with high lethalities. The fatality rates reported in different outbreaks ranged from 24-100%. In addition, sero-surveys conducted have shown different seropositivity for both Ebola and Marburg viruses. We aimed to use a meta-analysis approach to estimate the case fatality and seroprevalence rates of these filoviruses, providing vital information for epidemic response and preparedness in countries affected by these diseases...
November 25, 2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27853993/the-roles-of-ebolavirus-glycoproteins-in-viral-pathogenesis
#18
REVIEW
Yun-Jia Ning, Fei Deng, Zhihong Hu, Hualin Wang
Ebolaviruses are highly dangerous pathogens exhibiting extreme virulence in humans and nonhuman primates. The majority of ebolavirus species, most notably Zaire ebolavirus, can cause Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, in humans. EVD is associated with case-fatality rates as high as 90%, and there is currently no specific treatment or licensed vaccine available against EVD. Understanding the molecular biology and pathogenesis of ebolaviruses is important for the development of antiviral therapeutics...
November 14, 2016: Virologica Sinica
https://www.readbyqxmd.com/read/27846221/minimally-symptomatic-infection-in-an-ebola-hotspot-a-cross-sectional-serosurvey
#19
Eugene T Richardson, J Daniel Kelly, Mohamed Bailor Barrie, Annelies W Mesman, Sahr Karku, Komba Quiwa, Regan H Marsh, Songor Koedoyoma, Fodei Daboh, Kathryn P Barron, Michael Grady, Elizabeth Tucker, Kerry L Dierberg, George W Rutherford, Michele Barry, James Holland Jones, Megan B Murray, Paul E Farmer
INTRODUCTION: Evidence for minimally symptomatic Ebola virus (EBOV) infection is limited. During the 2013-16 outbreak in West Africa, it was not considered epidemiologically relevant to published models or projections of intervention effects. In order to improve our understanding of the transmission dynamics of EBOV in humans, we investigated the occurrence of minimally symptomatic EBOV infection in quarantined contacts of reported Ebola virus disease cases in a recognized 'hotspot.' METHODOLOGY/PRINCIPAL FINDINGS: We conducted a cross-sectional serosurvey in Sukudu, Kono District, Sierra Leone, from October 2015 to January 2016...
November 2016: PLoS Neglected Tropical Diseases
https://www.readbyqxmd.com/read/27795350/development-of-a-sensitive-and-specific-serological-assay-based-on-luminex-technology-for-detection-of-antibodies-to-zaire-ebola-virus
#20
Ahidjo Ayouba, Abdoulaye Touré, Christelle Butel, Alpha Kabinet Keita, Florian Binetruy, Mamadou S Sow, Vincent Foulongne, Eric Delaporte, Martine Peeters
The recent Zaire Ebola virus (EBOV) outbreak in West Africa illustrates clearly the need for additional studies with humans and animals to elucidate the ecology of Ebola viruses (EBVs). In this study, we developed a serological assay based on the Luminex technology. Nine recombinant proteins representing different viral regions (nucleoprotein [NP], 40-kDa viral protein [VP40], and glycoprotein [GP]) from four of the five EBV lineages were used. Samples from 94 survivors of the EBOV outbreak in Guinea and negative samples from 108 patients in France were used to calculate test performance for EBOV detection and cross-reaction with other Ebola virus lineages...
January 2017: Journal of Clinical Microbiology
keyword
keyword
15409
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"